Taurine
2-Aminoethanesulfonic Acid · The Ox-Bile Amino Acid
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The evidence splits sharply by claim. For the marketed longevity story the honest grade is preliminary (grade 2): Singh, Yadav and colleagues (Science 2023) showed taurine supplementation extends lifespan in worms and mice and improves healthspan markers in middle-aged monkeys, and reported that circulating taurine correlated inversely with several age-related conditions in humans. That is animal-causal plus human-associational, and it was directly undercut in 2025 when Fernandez and colleagues (Science 2025, an NIH-led longitudinal reanalysis across humans, monkeys and mice) found taurine generally stays flat or rises with age and concluded it is not a reliable aging marker, with two further 2025 human papers (Marcangeli et al., Aging Cell) finding no link between blood taurine and muscle mass, strength or physical performance. No completed human RCT shows taurine slows human aging. The cardiovascular signal is stronger but still modest: a 2024 systematic review and meta-analysis (Guan et al., Nutrition Journal) of 20 RCTs and 808 participants found small blood-pressure reductions overall and, in the heart-failure subgroup, improved NYHA class and a roughly 5-percent rise in ejection fraction, echoing the older Azuma double-blind crossover work. A 2024 metabolic-syndrome meta-analysis (Nutrition and Diabetes) reported reductions in fasting glucose, blood pressure and lipids. Averaged across the marketed halo and the specific supported uses, grade 2 is the honest overall figure, with heart failure alone nearer grade 3.
- FDA
- Legal supplement (DSHEA); GRAS food ingredient
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Very low risk at studied doses of 500 to 3,000 mg per day; EFSA set a high no-adverse-effect level and no serious adverse events are documented in routine use, though very-long-term high-dose safety is not fully characterized.
Taurine is a conditionally essential amino sulfonic acid the body uses for bile-acid conjugation, cell-volume regulation, calcium-signaling modulation, antioxidant defense and neurotransmission. It was first isolated from ox bile in 1827, which is where the name (from the Latin for bull) comes from. A 2023 Science paper reporting that taurine extends lifespan in mice moved it from energy-drink curiosity to headline longevity supplement almost overnight. The honest headline is that the longevity claim rests on animal and associational human data and was seriously challenged in 2025, while the more durable human signal is a modest one in heart failure and cardiovascular risk factors. It is among the safest supplements at studied doses.
From ox bile to energy drinks to longevity science, and a real Japanese cardiology heritage in between.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Taurine is 2-aminoethanesulfonic acid, a conditionally essential amino acid that is unusual in two ways. First, it contains a sulfonic acid group rather than the carboxylic acid group of standard amino acids, which changes its biochemistry substantially. Second, it is not incorporated into protein but circulates freely in plasma and accumulates in specific tissues at extremely high concentrations, particularly heart, skeletal muscle, brain, retina, and platelets. The body synthesizes taurine from cysteine via cysteine sulfinic acid decarboxylase (CSAD) in the liver, supplemented by dietary intake from seafood, meat, and (most prominently in early biochemistry) ox bile. The "conditional" nature reflects that endogenous synthesis is generally adequate in healthy adults but becomes insufficient in critical illness, premature infants (essential), patients on long-term parenteral nutrition, and possibly older adults. Taurine performs at least six distinct biochemical functions. It conjugates with bile acids in the liver to form taurocholic and taurochenodeoxycholic acids, the dominant bile-acid conjugation pathway in many mammals (humans use both taurine and glycine). It functions as an osmoregulator, accumulating in cells under hypertonic stress and protecting against volume changes. It modulates calcium signaling in cardiac and skeletal muscle through SERCA activity and L-type calcium channel modulation, the basis of its cardiac actions. It acts as a partial agonist at GABA-A and glycine receptors, producing modest inhibitory neurotransmission effects. It functions as an antioxidant, particularly in mitochondrial membranes through formation of 5-taurinomethyl-uridine in mitochondrial tRNA (essential for mitochondrial protein synthesis). And it modulates platelet aggregation and inflammatory cytokine production. The 2023 Singh, Yadav et al. Nature paper demonstrating that taurine supplementation extends lifespan in mice and improves healthspan markers in rhesus monkeys triggered the modern longevity supplement attention, though the framing as "the longevity amino acid" substantially exceeds what the human evidence currently supports.
How it is taken
The cardiovascular and metabolic evidence converges on 1.5-3g/day, typically taken in divided doses (2-3 times daily) with or without food. Heart failure protocols use the higher end (3-6g/day in some Japanese cardiology contexts) under specialist coordination. The Singh 2023 longevity work used substantially higher doses in mice scaled to body weight, direct human extrapolation is contested, but the human cardiovascular and metabolic dose range remains the practical recommendation. Taurine is water-soluble, well-absorbed, and produces plasma elevation within 60-90 minutes; chronic use produces accumulation in tissues (heart, skeletal muscle, brain) over weeks. The EFSA upper safe daily intake is 6g/day. Take with or without food, absorption is acceptable either way, though some users find food reduces minor GI sensitivity at higher single doses. Effects on cardiovascular and metabolic markers accumulate over 8-12 weeks; expect a quarter of consistent use before evaluating clinical change.
- General wellness
- 1-2g/day, divided
- Cardiovascular / metabolic
- 1.5-3g/day, divided
- Heart failure (cardiology-coordinated)
- 3-6g/day in divided doses
- Athletic recovery
- 1-3g/day around training
- EFSA upper safe daily intake
- 6g/day
- Time to plasma steady-state
- 2-4 weeks
- Time to clinical effect
- 8-12 weeks (cardiovascular, metabolic)
- Food state
- With or without food
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Pharmaceutical-Grade Crystalline Taurine
The form used in essentially all clinical trials. Pure white crystalline powder, water-soluble, essentially tasteless. Available from established supplement manufacturers (NOW Foods, Thorne, Pure Encapsulations, Bulk Supplements) at low cost per gram. Ideal for therapeutic doses (1-3g) where capsule pill count would be inconvenient.
Taurine Capsules
Capsule form typically delivers 500-1000mg per capsule. Acceptable for lower-dose protocols (500-1500mg/day) where pill count is reasonable. Pharmaceutical-grade taurine in capsule form is functionally equivalent to powder.
Taurine in Energy Drinks (Red Bull, Monster, Celsius)
Standard energy drink delivers 750-1000mg taurine per serving, a meaningful dose. The taurine itself is not problematic; the cardiovascular and metabolic concerns about energy drinks reflect caffeine content (often 80-300mg per can), sugar (or artificial sweeteners), and consumption patterns. The "taurine in energy drinks is dangerous" framing is a category error.
Taurine + Magnesium Combinations
Common cardiovascular and sleep formulations combining taurine with magnesium (often as magnesium taurate). Mechanistically reasonable, taurine and magnesium are complementary for calcium handling in cardiac muscle. Magnesium taurate specifically has emerging hypertension and cardiac arrhythmia evidence.
Magnesium Taurate (Combined Compound)
Magnesium bound to taurine, delivers both nutrients in a single chelated compound with calcium-handling synergy for cardiac and vascular tissue. The Brilla and Haley protocols for hypertension and arrhythmia use this form. Mechanistically elegant; clinically defensible.
Taurine in Infant Formula
Mandatory addition to infant formula since the 1980s after the Hayes cat work and subsequent human pediatric evidence demonstrated taurine essentiality in premature infants. The most-evidenced taurine use case anywhere, and the regulatory standard for infant nutrition globally.
Taurine + Caffeine Combinations
Pre-workout and "focus" formulations combining taurine with caffeine. Mechanistically reasonable, taurine modulates the cardiovascular and CNS effects of caffeine somewhat. The combination is the foundational chemistry of the energy drink category.
IV Taurine (Clinical Pharmaceutical)
Hospital and clinical IV nutrition formulations include taurine for premature infants, parenteral nutrition patients, and specific cardiac protocols. Not a consumer supplement form but the highest pharmaceutical-grade taurine source.
Who it works for, and who it does not
Congestive heart failure
The strongest cardiovascular evidence. Azuma 1985 series and subsequent Japanese cardiology trials support 3-6g/day taurine adjunct to standard heart failure therapy. Plasma taurine is depleted in heart failure (Imae 2014). Coordinate with cardiology; not substitute for guideline-directed therapy.
Type 2 diabetes / insulin resistance
Tahapary 2022 meta-analysis supports modest improvements in HbA1c, fasting glucose, and insulin sensitivity at 1.5-3g/day. Effect sizes smaller than metformin or GLP-1 agonists but meaningful as adjunct in metabolic syndrome populations.
Hypertension (mild to moderate)
Beyranvand 2011 and subsequent trials support modest BP-lowering effect at 1.5-3g/day taurine over 2-8 weeks. Effect size approximately 5-10 mmHg systolic in pre-hypertensive and mild hypertensive populations. Reasonable adjunct; not substitute for first-line antihypertensives in established hypertension.
Athletes (endurance and recovery)
Spiering 2007 and subsequent athletic trials support modest improvements in endurance markers, muscle damage reduction, and recovery at 1-3g/day. Effect sizes smaller than creatine or caffeine. Reasonable component of comprehensive sports nutrition protocols.
Eye health (retinal protection)
Taurine deficiency causes retinal degeneration in cats. Human retinal taurine status is generally adequate; specific supplementation indications include certain genetic conditions (taurine transporter deficiency) and possibly age-related macular degeneration prevention. Most healthy adults do not need targeted retinal taurine supplementation.
Premature infants
Taurine is conditionally essential in premature infants, endogenous synthesis is insufficient. Infant formula taurine fortification is the global regulatory standard. NICU parenteral nutrition includes taurine routinely. Not a consumer supplement context but among the most-evidenced taurine indications.
Healthy adults seeking longevity / general wellness
The post-Singh 2023 popular use case. Mouse and primate evidence is genuinely interesting; human longevity outcomes from supplementation are unproven. The 1-3g/day dose range used in cardiovascular and metabolic trials is reasonable; expectations should be calibrated to "modest cardiometabolic benefit" rather than "lifespan extension."
Energy drink heavy consumers
Heavy energy drink consumption can deliver 4-6g taurine daily from beverages alone, within the EFSA safe upper intake but at the high end. The cardiovascular concerns about energy drinks reflect caffeine, sugar, and consumption patterns rather than taurine. Worth considering when adding supplemental taurine to existing heavy energy drink use.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Magnesium (especially Magnesium Taurate)
The signature taurine pairing. Both nutrients support calcium handling in cardiac and vascular tissue. Magnesium taurate as a combined compound is the most elegant delivery, used in Brilla hypertension protocols. Common cardiovascular formulation.
CoQ10 / Ubiquinol
Mechanistically complementary for cardiovascular and mitochondrial endpoints. Both have heart failure evidence (Q-SYMBIO for CoQ10; Azuma for taurine). Common combination in cardiovascular protocols.
Omega-3 Fatty Acids
Complementary cardiovascular mechanisms. Both have heart failure adjunctive evidence. Common combination in comprehensive cardiac nutrition protocols.
Caffeine
Common in pre-workout and energy drink formulations. Taurine modestly moderates caffeine's cardiovascular and CNS effects in some studies; clinical significance is modest. The combination is well-tolerated and is the foundation of the energy drink category.
Creatine
Both amino acid derivatives with cardiac and skeletal muscle accumulation. Mechanistically complementary for performance and cardiovascular endpoints. Common in comprehensive athletic and aging-focused nutrition stacks.
Beta-Alanine
Both non-proteinogenic amino acid derivatives. Complementary mechanisms in skeletal muscle (taurine: calcium handling, osmoregulation; beta-alanine: carnosine pH buffering). Common in pre-workout combinations.
Antihypertensive medications
Additive BP-lowering effect with antihypertensive drugs. Monitor BP when initiating taurine in users on established antihypertensive therapy; medication dose adjustment may be needed.
Lithium
Theoretical interaction with lithium clearance through renal mechanisms. Worth monitoring lithium levels when initiating taurine in psychiatric patients on lithium therapy.
Heavy energy drink consumption
Heavy energy drink consumers may already receive substantial daily taurine (4-6g) from beverages. Adding supplemental taurine remains within safe range but worth accounting for cumulative intake.
What to look for on the label
Look for: USP or NSF third-party verification on the label; pure taurine specified without proprietary blend obscuring; powder or capsule form from established supplement manufacturers; reasonable price per gram (taurine is genuinely inexpensive, premium pricing without specific justification is suspect). Avoid: proprietary "energy" or "focus" blends that obscure individual taurine dose; products combined with high-dose caffeine without separate dosing options; products from manufacturers without third-party testing disclosure; energy drink-style combination products marketed as supplements (different regulatory category, generally lower quality control).
Safety in detail
- Among the safest supplements in routine use. EFSA established 6g/day as upper safe daily intake based on comprehensive review. No documented serious adverse events at studied doses across thousands of subject-exposures in clinical trials.
- Mild GI upset (nausea, mild stomach discomfort) is the most common side effect at high single doses; resolved by dividing dose or taking with food.
- Blood pressure lowering effect can be clinically meaningful, 5-10 mmHg systolic in pre-hypertensive and mild hypertensive populations. Monitor BP when initiating in users on antihypertensive medications.
- Mild antiplatelet activity at high doses (>3g/day); clinical bleeding events from taurine alone are rare. Pre-surgical discontinuation 1-2 weeks before elective procedures is conservative practice.
- Pregnancy and lactation: limited systematic safety data at supplemental doses. Endogenous taurine is essential during fetal development and present in breast milk; supplementation outside of established prenatal contexts not routinely recommended without OB-GYN guidance.
- Pediatric use: taurine is mandatory in infant formula and used routinely in pediatric clinical nutrition. Consumer pediatric supplementation outside formula or clinical contexts is generally not necessary in healthy children.
- Energy drink safety concerns reflect caffeine, sugar, and consumption patterns rather than taurine itself. The "taurine causes heart attacks" framing is a category error.
- Bipolar disorder: theoretical concern about taurine's inhibitory neurotransmitter effects in bipolar I patients; coordinate with psychiatry.
- Long-term safety profile is excellent across decades of energy drink consumption surveillance and clinical use.
What people get wrong
Often saidTaurine in energy drinks causes heart attacks.
ActuallyCategory error. Energy drink cardiovascular concerns reflect caffeine content (often 80-300mg per can), sugar, and consumption patterns, not taurine. The taurine itself is consistently exonerated in EFSA, FDA, and independent safety reviews.
Often saidTaurine is extracted from bull testicles or bovine bile.
ActuallyModern commercial taurine is chemical synthesis or bacterial fermentation, not animal-extracted for decades. The "bull testicles" framing in energy drink folklore is historical curiosity, not production reality.
Often saidTaurine is a stimulant.
ActuallyIt is not. Taurine acts as a partial agonist at GABA-A and glycine receptors, modest inhibitory neurotransmitter effects. The "energy" framing in energy drink marketing reflects the caffeine content, not the taurine.
Often saidThe 2023 longevity paper means taurine extends human lifespan.
ActuallyThe mouse evidence is real; primate healthspan markers improved; human longevity outcomes from supplementation are unproven. Cardiovascular and metabolic benefits at 1.5-3g/day are the human-evidenced use cases.
Often saidHigher dose is always better.
ActuallyEFSA upper safe daily intake is 6g/day. Most clinical evidence clusters at 1.5-3g/day. Higher doses have not been shown to produce proportionally better outcomes in human trials.
Often saidTaurine is essential for humans.
ActuallyIt is conditionally essential, endogenous synthesis is generally adequate in healthy adults but becomes insufficient in critical illness, premature infants (essential), parenteral nutrition patients, and possibly older adults.
Often saidVegan diets cause taurine deficiency.
ActuallyPlasma taurine is modestly lower in vegan adults but generally above deficiency thresholds. Vegans synthesize adequate taurine from precursors in most cases. The "vegan taurine deficiency" framing has been overstated in some animal-product advocacy.
Who profits, and who pushes back
Conservative longevity research community
The Singh 2023 Nature paper on lifespan extension in mice is a substantive contribution. The translation to human longevity outcomes remains unproven, most mouse lifespan interventions have failed to replicate in primates and humans. The framing of taurine as "the longevity amino acid" exceeds current evidence; cardiovascular and metabolic benefits at modest doses are the well-evidenced use cases.
Mainstream US cardiology
Despite the Japanese cardiology inheritance and the Azuma 1985 evidence, taurine has not been incorporated into US heart failure guidelines as routine therapy. Guideline-directed medical therapy (ACE inhibitors, beta blockers, MRAs, SGLT2 inhibitors) has substantially superior evidence. Taurine as adjunct may be reasonable; not substitute for established heart failure management.
Vijay Yadav
Lead investigator of the 2023 Nature paper on taurine lifespan extension. Among the most prominent academic voices on taurine's longevity potential. Independent academic; some industry collaborations disclosed.
David Sinclair
Mainstream longevity researcher who has discussed taurine in podcast and educational contexts post-2023. Independent academic; has commercial interests in related longevity supplements disclosed.
Andrew Huberman
Has covered taurine extensively post-Singh 2023 paper. Discusses mechanism, dosing, and stack combinations. No supplement-company sponsorship on taurine specifically; generally measured framing.
Peter Attia
Discusses taurine in cardiovascular and aging contexts. Has incorporated into his longevity protocol. Independent academic voice with measured framing.
Japanese cardiology community
Long-standing clinical use of taurine in Japanese heart failure protocols dating to Azuma 1985. Independent clinical inheritance distinct from US/European practice. Continues to use taurine as adjunctive therapy.
Energy drink industry
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Major commercial interest in taurine inclusion in energy drinks. The mass-market global taurine delivery vector. Substantial marketing of "performance" and "focus" attributes, though the dominant active compound in energy drinks is caffeine, not taurine.
Where the research comes from
| Place | Share of published research |
|---|---|
| Japan | 32% |
| United States | 24% |
| Europe | 22% |
| China | 12% |
| Other | 10% |
Research published from: Germany · Austria.
How we got here
Friedrich Tiedemann and Leopold Gmelin isolated taurine from ox bile in 1827 at the University of Heidelberg, naming it after Bos taurus, the species of cattle that provided the experimental material. The discovery was part of the broader characterization of bile chemistry that occupied early biochemistry; taurine's structural elucidation by Demarçay in 1838 established its sulfonic acid character as distinct from typical amino acids. For most of the 19th and early 20th centuries, taurine remained a biochemistry curiosity with limited clinical interest. The modern clinical era began with two parallel research threads. In the 1970s, Kenneth Hayes at Harvard demonstrated that cats developed retinal degeneration and dilated cardiomyopathy on taurine-deficient commercial diets, establishing the species-specific essentiality of taurine in feline nutrition and triggering the global addition of taurine to commercial cat foods (a major commercial industry change with substantial scientific backing). In Japan, the Azuma cardiology series in the 1980s explored taurine supplementation in congestive heart failure, establishing a clinical evidence base that persists in Japanese cardiology practice today. The 1985 Azuma trial is the foundational cardiac taurine evidence. The energy drink era began with Lipovitan-D in Japan (Taisho Pharmaceutical, 1962) which included taurine at substantial doses in its formulation. Red Bull (launched 1987 in Austria, adapted from the Thai Krating Daeng) brought the taurine-caffeine combination to global markets and built the modern $50B+ energy drink category. The 2000s-2010s saw substantial regulatory scrutiny of energy drinks but EFSA and FDA reviews consistently exonerated taurine itself, the concerns reflect caffeine, sugar, and consumption patterns. The modern longevity era began abruptly with the May 2023 Nature paper by Vijay Singh, Manish Yadav, and the broader Yadav laboratory consortium demonstrating taurine supplementation extended mouse lifespan and improved healthspan markers in rhesus monkeys. The paper triggered widespread mainstream media coverage and a substantial expansion of consumer interest beyond the energy drink and cardiac niches. Human longevity outcome trials are not yet available; the framing of taurine as "the longevity amino acid" substantially exceeds current human evidence but the cardiovascular and metabolic case has been strengthened by renewed research attention.
- 1827Tiedemann and Gmelin isolate taurine from ox bile at Heidelberg
- 1838Demarçay characterizes the sulfonic acid structure
- 1962Lipovitan-D launches in Japan with taurine, modern energy drink begins
- 1975Hayes establishes feline essentiality through retinal degeneration evidence
- 1980sMandatory taurine fortification of infant formula globally
- 1985Azuma heart failure trial, foundational Japanese cardiology evidence
- 1987Red Bull launches in Austria; global energy drink expansion
- 2007Spiering rugby athletic trial, sport supplementation evidence
- 2009EFSA energy drink safety review confirms taurine safety
- 2011Beyranvand hypertension trial
- 2014Imae demonstrates plasma taurine depletion in heart failure patients
- 2022Tahapary type 2 diabetes meta-analysis
- 2023Singh, Yadav et al. Nature paper on lifespan extension in mice and primates
- 2024Mainstream consumer "longevity supplement" reframing accelerates
What we do not know
- Whether the Singh 2023 mouse and primate longevity findings translate to human lifespan or healthspan endpoints, currently no human longevity trials.
- Whether the optimal supplementation dose for general healthspan differs from the established cardiovascular and metabolic doses (1.5-3g/day).
- Whether older adults experience age-related decline in endogenous taurine synthesis warranting routine supplementation.
- How the recent attention will affect the energy drink regulatory framework, particularly given the 4-6g/day intake potentially achievable through heavy energy drink consumption.
- Whether magnesium taurate as a combined compound has clinical advantages over separate taurine + magnesium supplementation.
- Whether taurine has specific applications in mitochondrial disease beyond general supportive nutrition.
- Whether the platelet aggregation modulation effects have clinical significance in cardiovascular prevention protocols.
- Whether bipolar I patients face specific concerns from taurine's inhibitory neurotransmitter activity, current data is theoretical.
Legal status
Universally available globally as a dietary supplement and food ingredient. GRAS (Generally Recognized As Safe) status in the US. EFSA established 6g/day upper safe daily intake. Approved for infant formula fortification globally, among the most universal regulatory standards in nutrition. Prescription IV formulations for parenteral nutrition. Common consumer brands include NOW Foods, Thorne, Pure Encapsulations, Designs for Health, Bulk Supplements. The energy drink category (Red Bull, Monster, Celsius, etc.) delivers substantial incidental taurine to mass consumer markets globally. Production is dominated by chemical synthesis (the natural extraction from ox bile is no longer commercially practiced); modern manufacturing is bacterial fermentation or chemical synthesis from inexpensive precursors.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Modern taurine production is dominated by chemical synthesis from inexpensive precursors (ethylene oxide and ammonium bisulfite, or aziridine and sulfurous acid), both processes producing pharmaceutical-grade material at commodity pricing. Bacterial fermentation taurine is also available and may be preferred by users seeking non-petrochemical sources. The "taurine from bull testicles" framing common in energy drink marketing folklore is historical curiosity, not modern production reality, commercial taurine has not been animal-extracted for decades. Quality variation across brands is modest given the simple molecule and well-established synthesis; third-party testing (NSF, USP, Informed Sport) provides standard verification.
At a glance
- Structure
- 2-aminoethanesulfonic acid (sulfonic acid amino acid)
- Body content
- High accumulation in heart, skeletal muscle, brain, retina, platelets
- Daily endogenous synthesis
- Generally adequate in healthy adults
- Standard supplement dose
- 1-3g/day
- Cardiac dose (Azuma)
- 3-6g/day
- EFSA upper safe daily
- 6g/day
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Taurine. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
Taurine supplementation extends lifespan in mice and improves healthspan in monkeys, with associational human data
Singh, Yadav et al., Science (Taurine deficiency as a driver of aging)
2025 NIH-led reanalysis found taurine does not reliably decline with age and is not a good aging marker
NIH conclusion that circulating taurine is unlikely to be a good aging marker; levels flat or rising with age
Blood taurine not associated with age, muscle mass, strength or physical performance in humans
Cardiovascular meta-analysis of 20 RCTs and 808 participants: modest blood-pressure reduction and heart-failure ejection-fraction gain
Guan et al., Nutrition Journal 2024 (Insights into cardiovascular benefits of taurine)
Taurine reduces metabolic-syndrome risk factors including glucose, blood pressure and lipids
Early double-blind crossover trial: taurine improved NYHA class in congestive heart failure
Beyranvand et al., Journal of Cardiology (taurine and exercise capacity in heart failure)
EFSA found taurine at energy-drink exposure not a safety concern; NOAEL 1,000 mg/kg/day
FDA GRAS notice covering taurine as a food ingredient
Dietary taurine deficiency causes dilated cardiomyopathy in cats, confirming its cardiac importance
Pion et al. / PMC (myocardial failure from taurine deficiency in cats)
Taurine first isolated from ox bile in 1827 by Tiedemann and Gmelin; name from Latin for bull
Functional roles of taurine in aging and cardiovascular health, mechanism overview
PMC review (Functional Role of Taurine in Aging and Cardiovascular Health)
The studies that matter
Tiedemann and Gmelin isolation1827
German chemists isolated taurine from ox bile. The name derives from Bos taurus, the species from which it was first extracted. Foundational biochemistry that named the compound and characterized its bile-acid conjugation role.
Hayes feline taurine deficiency1975
Kenneth Hayes (Harvard) demonstrated that cats develop retinal degeneration and dilated cardiomyopathy on taurine-deficient diets, establishing taurine essentiality in cats and changing the global cat food industry. Foundational nutritional science.
Azuma heart failure trial1985
Japanese cardiology trial in patients with congestive heart failure: 3-6g/day taurine improved cardiac function and NYHA class versus placebo. Foundational cardiac evidence; established Japanese clinical taurine inheritance.
Beyranvand isolated hypertension trial2011
Iranian RCT: 1.5g taurine twice daily for 2 weeks reduced systolic and diastolic blood pressure in pre-hypertensive young adults. Established the BP-lowering signal at modest doses.
Spiering rugby taurine trial2007
Sport supplementation trial showing 1.66g taurine improved several markers of muscle damage and oxidative stress in rugby players. Foundational athletic recovery evidence.
Imae et al. taurine deficiency in heart failure patients2014
Japanese clinical study demonstrating that heart failure patients have substantially lower plasma taurine than healthy controls, supporting taurine supplementation hypothesis.
Singh, Yadav et al. taurine longevityNature 2023
Multi-laboratory study: taurine supplementation in middle-aged mice extended median lifespan ~10-12%, improved healthspan markers, reduced cellular senescence, and improved mitochondrial function. Replicated in rhesus monkey healthspan markers. The paper that catapulted taurine into mainstream longevity attention.
Tahapary type 2 diabetes meta-analysis2022
Pooled analysis of taurine trials in T2D: meaningful improvements in HbA1c, fasting glucose, and insulin sensitivity at doses ~1.5-3g/day. Established the metabolic evidence beyond cardiac.
EFSA energy drink safety review2009, updated 2015
European Food Safety Authority comprehensive review concluded taurine in energy drinks at typical concentrations carries no documented safety concern at established consumption levels. Established the 6g/day upper safe daily intake.